Eprosartan mesylate, an angiotensin II receptor antagonist

被引:1
|
作者
Qian, Jing-Jing [2 ]
Hu, Xiu-Rong [1 ]
Gu, Jianming [1 ]
Wu, Su-Xiang [2 ]
机构
[1] Zhejiang Univ, Ctr Anal & Measurement, Hangzhou 310028, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou 310053, Zhejiang, Peoples R China
关键词
DOUBLE-BLIND; HYPERTENSION; MULTICENTER; BEHAVIOR;
D O I
10.1107/S1600536811006659
中图分类号
O7 [晶体学];
学科分类号
0702 ; 070205 ; 0703 ; 080501 ;
摘要
The title compound, eprosartan mesylate {systematic name: 2-butyl-1-(4-carboxybenzyl)-5-[(E)-2-carboxy-3-(thiophen-2-yl)prop-1-enyl]-1H-imidazol-3-ium methanesulfonate}, C23H25N2O4S+center dot CH3O3S-, one of the angiotensin II-receptor antagonists, is effective in regulating hypertension, induced or exacerbated by angiotensin II, and in the treatment of congestive heart failure, renal failure and glaucoma. In the eprosartan residue, which appears in this crystal in the cationic imidazolium form, the benzene ring plane is almost orthogonal to that of the imidazole ring, making a dihedral angle of 87.89 (2)degrees. The thiophene ring forms dihedral angles of 66.54 (2) and 67.12 (2)degrees with the benzene and imidazole rings, respectively. The imidazolium NH group and the H atom of the aromatic carboxyl group participate in hydrogen bonds with the the O atoms of the anion, thus forming centrosymmetric aggregates made up of two cations and two anions each. The second carboxyl group further links the above-mentioned aggregates through a conventional centrosymmetric hydrogen-bonding motif into infinite chains along [011].
引用
收藏
页码:O770 / U1389
页数:13
相关论文
共 50 条
  • [1] Review of eprosartan: A new angiotensin II receptor antagonist - Summary
    Sica, DA
    PHARMACOTHERAPY, 1999, 19 (04): : 108S - 109S
  • [2] Review of eprosartan: A new angiotensin II receptor antagonist - Introduction
    Hollenberg, NK
    PHARMACOTHERAPY, 1999, 19 (04): : 71S - 72S
  • [3] Drug interaction studies with eprosartan, a novel angiotensin II receptor antagonist
    Ilson, B
    JOURNAL OF HYPERTENSION, 1998, 16 : S240 - S240
  • [4] Overview of the clinical pharmacology of eprosartan, a novel angiotensin II receptor antagonist
    Ilson, B
    JOURNAL OF HYPERTENSION, 1998, 16 : S234 - S234
  • [5] Gene expression in rats with renal disease treated with the angiotensin II receptor antagonist, eprosartan
    Wong, VY
    Laping, NJ
    Contino, LC
    Olson, BA
    Grygielko, E
    Brooks, DP
    PHYSIOLOGICAL GENOMICS, 2000, 4 (01) : 35 - 42
  • [6] EVALUATION OF THE ANGIOTENSIN-II RECEPTOR ANTAGONIST, EPROSARTAN, BY CASUAL AND AMBULATORY BP MONITORING
    WHITE, WB
    MANSOOR, GA
    LESSEM, J
    SCHUSTERMAN, N
    CLINICAL RESEARCH, 1994, 42 (03): : A447 - A447
  • [7] Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan valsartan or irbesartan: Relationship to differences in prejunctional angiotensin II receptor blockade
    Ohlstein, EH
    Brooks, DP
    Feuerstein, GZ
    Ruffolo, RR
    PHARMACOLOGY, 1997, 55 (05) : 244 - 251
  • [8] Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus
    Martin, DE
    DeCherney, GS
    Ilson, BE
    Jones, BA
    Boike, SC
    Freed, MI
    Jorkasky, DK
    JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (02): : 155 - 159
  • [9] The clinical profile of the angiotensin II receptor blocker eprosartan
    Hedner, T
    JOURNAL OF HYPERTENSION, 2002, 20 : S33 - S38
  • [10] EFFECTIVENESS OF ANGIOTENSIN II RECEPTOR ANTAGONIST EPROSARTAN IN PATIENTS WITH ISOLATED SYSTOLIC HYPERTENSION AND EPISODES OF ATRIAL FIBRILLATION
    Vatinian, S.
    Gurgenyan, S.
    Nikoghosyan, K.
    JOURNAL OF HYPERTENSION, 2009, 27 : S371 - S372